Medifast, Inc. reported first‑quarter 2026 results that included revenue of $76.0 million, up 19.2% from $63.5 million in the same period a year earlier, and a net loss of $2.1 million, or $0.19 per diluted share. The company’s coach‑based business model showed a positive trend, with revenue per active earning coach rising to $5,432 and the active coach count at 14,000, a 19.2% year‑over‑year increase in coach productivity that represents the highest quarterly gain in five years and the highest sequential increase in eight years.
Gross profit margin contracted to 68.1% from 72.8% year‑over‑year, reflecting a loss of leverage on fixed costs as revenue declined. The company’s cash position remains strong, with $168.9 million in cash, cash equivalents and investments and no debt. Medifast reiterated its 2026 guidance, projecting revenue of $270–$300 million and a full‑year loss per share of $1.55–$2.75. The guidance signals a continued focus on cost discipline and a path toward profitability in the fourth quarter of 2026.
The earnings beat analyst expectations for earnings per share, with a loss of $0.19 versus consensus estimates ranging from –$0.36 to –$0.55. The beat of $0.36 per share was driven by disciplined cost management and a higher mix of higher‑margin coach‑led services, offsetting the revenue decline caused by the rapid adoption of GLP‑1 weight‑loss medications that have eroded the traditional weight‑loss market.
Revenue missed the consensus estimate of $85.5 million, a shortfall attributed to the loss of market share in legacy weight‑loss segments and the shrinking coach base. However, the company’s focus on metabolic health and the launch of new product lines are expected to stabilize revenue growth in the coming quarters.
Management emphasized that the company is on a path to profitability, citing the launch of a new product line in Q4 2026 and anticipated cost savings of more than $30 million. CEO Daniel Chard noted that the company’s “metabolic health strategy” is positioned to address the broader health crisis and that the improved coach productivity is a leading indicator of future growth.
The company’s guidance for 2026 revenue and loss per share remains unchanged from the prior quarter, indicating confidence in the current trajectory while acknowledging the need for continued cost discipline and market adaptation.
revised_sentiment_rating
}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.